Application of Cyperturonone in preparation of medicine for treating influenza A virus infection

By using natural small molecule Cyperotundone to inhibit influenza A virus and preparing different dosage forms of drugs in combination with pharmaceutical carriers, the effectiveness and safety of influenza A virus treatment in the prior art are solved, and an efficient and safe treatment plan is provided. Response to the global flu epidemic.

CN118924713APending Publication Date: 2024-11-12SHANGHAI JIAOTONG UNIV SCHOOL OF MEDICINE
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202411055971.6
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2024-08-02
Publication Date
2024-11-12

AI Technical Summary

Technical Problem

The prior art lacks effective drugs to inhibit influenza A virus, and traditional chemical synthetic drugs may bring side effects, affecting safety and social promotion.

Method used

Using the natural Chinese medicine small molecule Cyperotundone, a drug of different dosage forms is prepared by inhibiting the infection and replication of influenza A virus, combined with pharmaceutically acceptable carriers, including injections, powders, capsules, etc., to provide an efficient and safe treatment plan.

Benefits of technology

Cyperotundone shows strong inhibitory power and high inhibitory efficiency. It has low IC50 value and low cytotoxicity for influenza A virus, providing a safe and effective treatment plan, avoiding the side effects of chemical synthetic molecules, and is suitable for the treatment of respiratory system. Diseases such as infection and pneumonia have provided new treatments for the global influenza epidemic.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN118924713A_ABST
    Figure CN118924713A_ABST
Patent Text Reader

Abstract

The invention provides application of Cyperotudinone in preparation of a medicine for treating influenza A virus infection, and belongs to the technical field of biological medicine. According to the application disclosed by the invention, the small molecule Cyperotudinone has relatively strong inhibition force on the influenza A virus, IC50 is equal to 0.45 mu M, the value is relatively low, and the inhibition efficiency is relatively high; the invention also detects the toxicity condition of the Cypertudinone to cells, and finds that the Cypertudinone has low toxicity to cells and high CC50, the selection index (SI) is far higher than the safety range, and the safety and effectiveness of the Cypertudinone as an IAV influenza A virus inhibitor are better guaranteed. Cyperotudinone can be used for treating diseases such as respiratory system infection, pneumonia and encephalitis caused by influenza A viruses, and a new effective treatment medicine is provided for global influenza epidemic situations.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present invention relates to the field of biomedical technology, and in particular to application of Cyperotundone in preparing medicine for treating influenza A virus infection. Background Art

[0002] Influenza A virus (IAV) is a human respiratory pathogen that is widely prevalent around the world. It is highly contagious and pathogenic, and can cause severe respiratory infections, pneumonia, encephalitis and other diseases, and even worse, can lead to death. Influenza A virus belongs to the family of Orthomyxoviridae and is an enveloped negative-strand RNA virus. It can be divided into several subtypes, such as H1N1, H3N2, etc., based on the different antigenic properties of the hemagglutinin protein (HA) and neuraminidase protein (NA) on its surface.

[0003] IAV is also a zoonotic pathogen with multiple hosts. It can be transmitted between species and reclassified into different virus types, which in turn leads to the emergence and widespread spread of new influenza virus epidemics. Among them, the Spanish flu outbreak between 1918 and 1919 was the most serious, causing more than 40 million deaths. Currently, there are few specific drugs for the treatment of influenza A virus, so drugs that have an inhibitory effect on influenza A virus have always been the focus of researchers.

[0004] The method of using natural chemical components extracted from typical Chinese medicine to inhibit IAV has strong medical value and clinical potential, and is in line with the general research direction of combining Chinese and Western medicine. Compared with the artificially synthesized small molecules of medicinal chemistry previously used to inhibit IAV, the natural chemical molecules extracted from plant components can more effectively avoid the possible side effects of chemical synthetic molecules on humans, and are more secure in terms of safety and social promotion.

[0005] Cyperus rotundus, also known as aconite, was first recorded in the Compendium of Materia Medica: "It is cold and epidemic in times of crowing, and it benefits the three burners. It relieves the six du, eliminates food accumulation, phlegm and fluid distension, visceral swelling, abdominal distension, beriberi, and stops pain in the heart, abdomen, limbs, head, eyes, teeth, and ears, carbuncle, ulcer, vomiting blood, bleeding, hematuria, metrorrhagia, leukorrhea, irregular menstruation, and all kinds of diseases before and after pregnancy." "Decoction and drinking can disperse qi stagnation, benefit the chest and diaphragm, and reduce phlegm and heat." It has the effects of promoting bile secretion; inhibiting ileal smooth muscle; relaxing uterine smooth muscle; having estrogen-like effects; hypnotic; antipyretic; cardiotonic; anti-pathogenic microorganisms; anti-inflammatory, etc.

[0006] The natural Chinese medicine small molecule compound Cyperotundone is a terpene compound isolated from Cyperus rotundus. It was isolated in 1965 (Hikino H, Aota K, Takemoto T. Structure of Cyperotundone [J]. Chemical & Pharmaceutical Bulletin, 1965, 13 (5): 628. DOI: 10.1248 / cpb.13.628.) and is one of the natural active ingredients of Cyperus rotundus. It is a waxy solid at low temperature and an oily liquid at room temperature. Its molecular formula is C 15 H 22 O.

[0007] In the current research on the small molecule Cyperotundone, it was found that Cyperotundone can inhibit the activity of MCF-7 and MCF-7 / ADR cells in breast cancer, and induce apoptosis of MCF-7 and MCF-7 / ADR cells, thereby improving the sensitivity of cancer treatment chemotherapy; this small molecule also has the effect of a potential selective estrogen regulator. In addition, it has antibacterial, anti-inflammatory, and anti-epileptic effects in pneumonia patients. It is already a mature drug small molecule and is derived from natural plant ingredients. It has low toxicity to normal cells and high safety. It has the safety prerequisite to become a good inhibitor of influenza A virus.

[0008] However, there are currently few reports on the antiviral effects of the small molecule Cyperotundone. Therefore, further development of the antiviral effects of Cyperotundone is of great significance to solving the global influenza epidemic. Summary of the invention

[0009] The purpose of the present invention is to provide the use of Cyperotundone in the preparation of a drug for treating influenza A virus infection. Cyperotundone has a strong inhibitory effect and a high inhibitory efficiency on influenza A virus, low cytotoxicity and high safety.

[0010] In order to achieve the above-mentioned object of the invention, the present invention provides the following technical solutions:

[0011] The present invention provides application of Cyperotundone in preparing medicine for treating influenza A virus infection.

[0012] Furthermore, the structure of Cyperotundone is shown in formula (I):

[0013]

[0014] Furthermore, the Cyperotundone can inhibit the infection and replication of influenza A virus.

[0015] Furthermore, the drug for treating influenza A virus infection may be added with a pharmaceutically acceptable carrier.

[0016] Furthermore, the dosage form of the drug for treating influenza A virus infection is one of injection, powder, capsule, granule, tablet, pill, and ointment.

[0017] The beneficial effects of Cyperotundone described in the present invention compared with the prior art are as follows:

[0018] (1) The present invention utilizes the small molecule Cyperotundone to inhibit influenza A virus and detects the IC value of the inhibitory effect of Cyperotundone 50 The results showed that Cyperotundone has a strong inhibitory effect on influenza A virus, IC 50= 0.45μM, which is a low value and has a high inhibition efficiency. The toxicity of the small molecule Cyperotundone to cells was also tested and found that its toxicity to cells was also low. 50 The selectivity index (SI) is much higher than the safety range, which provides better assurance for the safety and efficacy of Cyperotundone as an IAV influenza A virus inhibitor.

[0019] (2) The present invention uses a natural chemical component extracted from plants - a small molecule Cyperotundone to inhibit influenza A virus, which can effectively avoid the side effects of chemically synthesized molecules and has high safety. In addition, the small molecule Cyperotundone has a high inhibition efficiency on influenza A virus. It can be used to treat respiratory infections, pneumonia, encephalitis and other diseases caused by influenza A virus, providing a new effective therapeutic drug for the global influenza epidemic. BRIEF DESCRIPTION OF THE DRAWINGS

[0020] In order to more clearly illustrate the embodiments of the present invention or the technical solutions in the prior art, the drawings required for use in the embodiments will be briefly introduced below. Obviously, the drawings described below are only some embodiments of the present invention. For ordinary technicians in this field, other drawings can be obtained based on these drawings without paying creative labor.

[0021] Figure 1 This is the cytotoxicity curve of Cyperotundone and the inhibition rate curve of IAV in Experimental Example 1. DETAILED DESCRIPTION

[0022] The embodiments of the present invention are described in detail below, and the embodiments are intended to explain the present invention and should not be construed as limiting the present invention. If specific techniques or conditions are not specified in the embodiments, they are carried out according to the techniques or conditions described in the literature in this area or according to the product specifications. If the manufacturers of reagents or instruments are not specified, they are all conventional products that can be obtained commercially.

[0023] Various exemplary embodiments of the present invention will now be described in detail. This detailed description should not be considered as limiting the present invention, but should be understood as a more detailed description of certain aspects, features, and embodiments of the present invention.

[0024] If no specific techniques or conditions are specified in the examples, the techniques or conditions described in the literature in the field or the product instructions are used. If no manufacturer is specified for the reagents or instruments used, they are all conventional products that can be purchased commercially.

[0025] The manufacturer of the small molecule Cyperotundone used in the following examples of the present invention is targetmo, with product number T5709 CAS 3466-15-7.

[0026] The present invention utilizes Cyperotundone to treat MDCK cells, and simultaneously infects the MDCK cells with IAV-Gluc to detect the inhibitory effect and cytotoxicity of Cyperotundone on IAV.

[0027] The results showed that Cyperotundone has a strong inhibitory effect on influenza A virus, IC 50= 0.45μM, a low value. 50 =104.3μM, the higher the value, the lower the toxicity to cells.

[0028] The Cyperotundone of the present invention belongs to terpenoid compounds, and its molecular formula is: 15 H 22 O, molecular weight: 218.33, structure see formula (I):

[0029]

[0030] Solubility: DMSO: 55 mg / mL (251.9 mM)

[0031] Example 1

[0032] Example 1 of the present invention screens drugs for inhibiting influenza A virus, specifically comprising the following steps:

[0033] Preliminary screening of small molecules with IAV inhibitory activity in the drug small molecule library:

[0034] The concentration of drug small molecules in the small molecule library is 10mM (in DMSO). The screened IAV is connected to a gene expressing Gaussia Luciferase (Gluc) luciferase. The infection and replication of the virus in the host cells can be obtained by detecting the value of luciferin after infecting the cells.

[0035] The small molecule Cyperotundone in the small molecule library was diluted 1000 times to 10 μM in Mock DMEM, and then the IAVA / PR / 8 / 34 (PR8)-Gluc strain was added to it. The titer of the original venom was 1.0×10 5 The final venom concentration was diluted 100 times and mixed with MDCK cells for 24 hours before the cells were tested for fluorescence (Gaussia-Lumi TM Gaussia luciferase reporter gene detection kit, Bio-Tech Biotechnology), and added positive control group and negative control group of IAV virus-infected and virus-free pure cells for luciferin detection. It was finally found that the luciferin value of Cyperotundone was close to the luciferin detection value of the pure cell control group, while the luciferin detection values ​​of most other small molecules were close to the luciferin value of the control group of IAV-infected cells only. The inhibition rate of Cyperotundone on IAV was close to 100%.

[0036] Example 2

[0037] In Example 2 of the present invention, a tablet-type influenza A virus infection-resistant drug is prepared using Cyperotundone, and the specific preparation method is as follows:

[0038] Take Cyperotundone, add conventional excipients for preparing tablets, mix well, and compress into tablets.

[0039] Example 3

[0040] Example 3 of the present invention uses Cyperotundone to prepare an anti-influenza A virus infection granule, and the specific preparation method is as follows:

[0041] Take Cyperotundone, add the conventional auxiliary materials for preparing granules, mix well, and package.

[0042] Example 4

[0043] In Example 4 of the present invention, an aerosol anti-influenza A virus infection drug is prepared using Cyperotundone, and the specific preparation method is as follows:

[0044] Cyperotundone is taken and conventional excipients for preparing aerosols such as propellants and various additives are added for filling.

[0045] Example 5

[0046] Example 5 of the present invention uses Cyperotundone to prepare a capsule-based drug for preventing influenza A virus infection. The specific preparation method is as follows:

[0047] Take Cyperotundone, add conventional excipients for preparing capsules, mix well, quantitatively fill into a capsule shell made of gelatin as the main material and seal it.

[0048] Test Example 1

[0049] Experimental Example 1 of the present invention detected the inhibitory effect of Cyperotundone on IAV and its cytotoxicity, and the specific method was as follows:

[0050] (1) Inhibition effect detection:

[0051] The small molecule Cyperotundone was diluted in Mock DMEM to concentrations of 50 μM, 25 μM, 10 μM, 5 μM, 2.5 μM, 1 μM, 0.1 μM, and 0.01 μM. Different concentrations of Cyperotundone were used to treat MDCK cells. At the same time, the MDCK cells were infected with IAV-Gluc. Luciferase detection was performed and the values ​​were read 24 hours after infection. The curve analysis of the results was then performed to finally obtain the small molecule concentration value IC at which the inhibition rate reached half. 50 , the results are shown in Figure 1 .

[0052] (2) Cytotoxicity assay:

[0053] The small molecule Cyperotundone was diluted in Mock DMEM to concentrations of 1000μM, 500μM, 250μM, 166.67μM, 100μM, 50μM, 50μM, 25μM, 10μM, 5μM, 2.5μM, 1μM, 0.33μM, 0.1μM, and 0.01μM, and cells were incubated with different concentrations of the small molecule Cyperotundone. Five groups of cells under the same conditions were set up for average control, and the cytotoxicity was measured by the CCK8 kit (Enhanced Cell Counting Kit-8 Biyuntian Biotechnology). The cytotoxicity curve of the small molecule was drawn, and the curve analysis of the results was performed to finally obtain the small molecule concentration value CC at which the cytotoxicity reached half 50 , the results are as follows Figure 1 shown.

[0054] Depend on Figure 1 It can be seen that Cyperotundone has a strong inhibitory effect on influenza A virus, IC 50= 0.45μM, a low value. 50=104.3 μM, which is a relatively high value, has a lower toxicity to cells, and the selectivity index (SI) is much higher than the safe range, which provides greater assurance for the safety and effectiveness of Cyperotundone as an IAV influenza A virus inhibitor.

[0055] The above is only a preferred embodiment of the present invention. It should be pointed out that for ordinary technicians in this technical field, several improvements and modifications can be made without departing from the principle of the present invention. These improvements and modifications should also be regarded as the scope of protection of the present invention.

Claims

1. Application of cyperotundone in the preparation of drugs for treating influenza A virus infection.

2. The use of Cyperotundone according to claim 1 in the preparation of a drug for treating influenza A virus infection, characterized in that: The structure of Cyperotundone is shown in formula (I):

3. The use of Cyperotundone in the preparation of a drug for treating influenza A virus infection according to claim 2, characterized in that: The cyperotundone can inhibit the infection and replication of influenza A virus.

4. The use of Cyperotundone in the preparation of a drug for treating influenza A virus infection according to claim 3, characterized in that: The drug for treating influenza A virus infection may be added with a pharmaceutically acceptable carrier.

5. The use of Cyperotundone in the preparation of a drug for treating influenza A virus infection according to claim 4, characterized in that: The dosage form of the drug for treating influenza A virus infection is one of powder, solution, capsule, granule, tablet, emulsion and suspension.